Access to capital, government red tape among top barriers cited by biotech firms, survey finds

Though the industry believes the federal government's flagship innovation program, SR&ED, is important and useful, all say it could use some tweaks.

A scientist working at Spartan, a biotech firm located in Ottawa, is pictured in 2017. The biotech industry in Canada is expanding, although investment issues remain, according to a recent survey.The Hill Times photograph by Sam Garcia

News

BY JOLSON LIM

September 26, 2018

Access to capital remains the biggest challenge for Canada’s biotechnology sector, even as most of its companies have tapped into federal programs offered to startup companies, according to a new report released on Sept. 24. Whi...

To keep reading, subscribe and become a political insider.

Only $7.76 a week for an annual subscription.

Enjoy unlimited website access and the digital newspaper.

Cancel anytime.

Already a Subscriber?

Get Tuesdays: Innovation & Industry Newsletter

The policies, decisions, and people working on investment and regulation in the industry and innovation realm.

By entering your email address you consent to receive email from The Hill Times containing news, analysis, updates and offers. You may unsubscribe at any time. See our privacy policy